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Abstract
Background: The genes of base excision repair (BER) pathway have been extensively studied in
the association with various human cancers. We performed a case-control study to test the
association between two common single nucleotide polymorphisms (SNPs) of XRCC1 gene with
human head and neck squamous cell carcinoma (HNSCC).
Methods:  The genotype analysis of Arg194Trp and Arg399Gln gene polymorphisms for 92
HNSCC patients and 124 controls of cancer free subjects, in Polish population were performed
using the PCR-based restriction fragment length polymorphism (PCR-RFLP) with endonuclease
MspI.
Results: No altered risk has been found individually for these SNPs, however haplotypes analysis
showed high association with head and neck cancer. The highest frequency, according to wild-type
of Arg194Arg and Arg399Arg genotypes, was identified for Arg194Trp-Arg399Arg haplotype (OR,
2.96; 95% CI, 1.01–8.80).
Conclusion: Finally, we identified the combined Arg194Trp-Arg399Arg genotype of base excision
repair gene XRCC1 that was associated with HNSCC and may have an impact on identification of
a high-risk cancer population.
Background
Genome integrity is maintained by an intricate network of
DNA repair proteins [1,2]. Organisms have developed
several DNA repair pathways as well as DNA damage
checkpoints. Although each pathway is addressed individ-
ually, the cross talk exists between repair pathways, and
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there are instances in which a DNA-repair protein is
involved in more than one pathway. Single nucleotide
polymorphisms (SNPs) in DNA repair genes may be asso-
ciated with differences in the repair efficiency of DNA
damage and may influence an individual's risk of cancer.
Establishing this connection, however, has been a chal-
lenge due to the complexity of interactions that affect the
repair pathways [3,4]. Increasing evidence links environ-
mental exposures, subtle modification in DNA repair effi-
ciency, and cancer risk [5].
The genes belonging to base excision repair (BER) path-
way, such as X-ray Repair Cross Complementing Group 1
(XRCC1) have been extensively studied in the association
with various human cancer [6-14]. Two major SNPs of the
XRCC1 gene have been identified at codon 194 (C > T
substitution at position 26304, exon 6, Arg to Trp) and
399 (G > A substitution at position 28152, exon 10, Arg to
Gln). The XRCC1 Arg399Gln polymorphism is located in
the area coding for a PARP binding site. PARP is a zinc-
fnger containing enzyme that detects DNA strand breaks
[15]. Carriers of the XRCC1 399 Gln variant allele have
been shown to have higher levels of DNA adducts [16]
and to be at greater risk for ionizing radiation sensitivity
[17] and tobacco correlated DNA damage [18-20].
The XRCC1 protein plays an important role in the main-
tenance of genomic stability through the both base exci-
sion and single-strand break repair by acting as a scaffold
for other DNA repair proteins, such as DNA glycosylases,
polymerase beta [21] and ligase III [22]. XRCC1 partici-
pates in the first step of BER by interacting with the
numerous of human DNA glycosylases including
hOGG1, MPG, hNTH1 and NEIL1 [23,24]. It was found
that XRCC1, through its NTD and BRCT1 domains, has
affinity to form a covalent complex via Schiff base with AP
sites. It was also reported that XRCC1 affinity was higher
when the DNA carried an AP-lyase- or APE1-incised AP
site [25]. This results in an acceleration of the overall
repair process of abasic site, which can be used as a sub-
strate by DNA polymerase beta. Thus, this suggests mech-
anism by which XRCC1, through its multiple protein-
protein interactions plays essential role in the resealing of
the repaired DNA strand.
Head and neck squamous cell carcinoma (HNSCC) com-
prise about 6% of all malignant neoplasm. Overall sur-
vival is low especially in developing countries and the
major risk factors of HNSCC became smoking or alcohol
consumption [26]. Although the functional significance
of XRCC1 polymorphism has not yet been fully eluci-
dated, due to smoking and alcohol consumption attitude
it may increase risk of head and neck cancer occurrence
[27]. To test this hypothesis, we performed a hospital
based case-control study using a polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-
RFLP) assay to genotype two polymorphisms of DNA
repair gene XRCC1 Arg194Trp and Arg399Gln in relation
to head and neck cancer susceptibility.
Methods
Patients
Blood samples were obtained from 92 patients (50 men
and 42 women, mean age 48.7 ± 11.13) with squamous
carcinoma of head and neck. Control samples consisted
of age matched 124 cancer-free blood donors (63 men
and 61 women, mean age 44.47 ± 19.24). Despite of 4
years younger controls then patients, there were not statis-
tical differences in age of analyzed groups (P = 0.169).
Prior to examination, the patients and control subjects,
did not receive medicaments like antibiotics or steroids.
Patients enrolled to the examination were analyzed
according to cancer staging system of the TNM Classifica-
tion of Malignant Tumours that describes the extent of
cancer in a patient's body: T describes the size of the
tumor and whether it has invaded nearby tissue, N
describes regional lymph nodes that are involved and M
describes distant metastasis (spread of cancer from one
body part to another). Within the control group selected
subjects (52 cases) were classified as smokers for at least
10 years, up to 10 cigarettes per day. The smoking attitude
of head and neck cancer group was also analyzed for non-
smoking patients, patients smoking 10 cigarettes per day
for ten years, patients smoking 20 cigarettes per day for
twenty years and patients smoking 20 cigarettes per day
for thirty years. All patients and controls subjects were
recruited from three medical units of Head and Neck Neo-
plasm Surgery Departments, Medical University of Lodz,
Poland. All subjects included into the study were unre-
lated Caucasians and inhibited Lodz district, Poland. The
study was approved by the Local Ethic Committee and
written consent was obtained from each patient or healthy
blood donor before enrolling into the study.
Genotype determination
Genomic DNA was isolated from blood cells using Phe-
nol-Chloroform extraction method. Genotypic analysis of
the XRCC1 399 G > A polymorphism was determined by
the PCR-based restriction fragment length polymorphism
(PCR-RFLP) method, as described in detail earlier [28].
Briefly, PCR primers for the XRCC1 codon 194 (forward
5'-GCCCCGTCCCAGGTA-3' and reverse 5'-AGCCCCAA-
GACCCTTTCATC-3') were used to generate a 292 bp
product containing the polymorphic sites. PCR primers
for the XRCC1 codon 399 (forward 5'-TTGTGCTTTCTCT-
GTGTCCA-3' and reverse 5'-TCCTCCAGCCTTTTCTGATA-
3') were used to generate a 615 bp product containing the
polymorphic sites. The PCR was carried out in a MJ
Research, INC thermal cycler, model PTC-100 (Waltham,
MA, USA). The PCR reactions were carried out in a 20 μlJournal of Experimental & Clinical Cancer Research 2009, 28:37 http://www.jeccr.com/content/28/1/37
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volume of 20 pmol of each primer, 0.2 mM each dNTP
and 1 μl buffer and 1 U of Taq polymerase, with a dena-
turation of 94°C for 5 min, followed by 30 cycles of 30 s
at 61°C and 45 s at 72°C and finally 7 min at 72°C. Fol-
lowing amplification, PCR products were digested using
10 U of restriction enzyme MspI (New England BioLabs,
Beverly, MA, USA) for 16 h at 37°C, and electrophoresed
on a 3% agarose gel. The wild type Arg allele for codon
194 is determined by the presence of a band at 292 bp,
while the mutant Trp allele is determined by the presence
of a band at 313 bp (indicative of the absence of the MspI
cutting site). In addition to these bands, a 174 bp band,
resulting from an additional invariant cutting site for MspI
in the 491 bp amplified fragment (codon 194) is always
present and serves as internal control for complete MspI
digestion. The wild type Arg allele for codon 399 is deter-
mined by the presence of two bands at 374 and 221 bp,
while the mutant Gln allele is determined by the presence
of the uncut 615 bp band (indicative of the absence of the
MspI cutting site).
Data analysis
The allelic frequencies were estimated by gene counting
and genotypes were scored. The χ2 test was used to com-
pare the observed numbers of genotypes with those
expected for a population in the Hardy-Weinberg equilib-
rium and to test the significance of the differences of
observed alleles and genotypes between groups. The odds
ratios (ORs) and 95% confidence intervals (CIs) were cal-
culated by using a logistic regression model. The t-test (for
normal distribution) or Manne-Whitney test (for non-
normal distribution) was used to compare each parameter
between two groups (i.e. sex and age). An analysis of var-
iance test was used to identify parameters that would
make significant differences between more than two
groups; Scheffe's test was then used to assess the signifi-
cance of difference in each identified parameter between
any two groups. STATISTICA 6.0 software (Statsoft, Tulsa,
OK, USA) was used to perform analyses.
Results and discussion
In this work we investigated two common single nucle-
otide polymorphisms of XRCC1  gene Arg194Trp and
Arg399Gln and their association with human head and
neck squamous cell carcinoma. The genotype analysis of
these two SNPs of XRCC1 gene, for 92 HNSCC patients
and 124 controls of cancer free subjects, in Polish popula-
tion were performed using PCR-RFLP method. The poly-
morphisms chosen for this study have been shown to
have functional significance and may be responsible for a
low DNA repair capacity phenotype characteristic of can-
cer patients including head and neck squamous carcino-
mas [29-32]. The characteristic of HNSCC patens group
according to age, sex, tumor stage and smoking status data
was displayed in table 1.
Genome integrity is maintained by an intricate network of
DNA repair proteins [33,34]. Organisms have developed
several DNA-repair pathways as well as DNA-damage
checkpoints. Defects in this complex machinery are asso-
ciated with genotoxic susceptibility and familial predispo-
sitions to cancer [35]. Increasing evidence links
environmental exposures, subtle modification in DNA
repair efficiency, and cancer risk [36]. XRCC1 participates
in DNA single strand break and base excision repair to
protect genome stability in mammalian cells. One of the
common polymorphisms of XRCC1  the Arg399Gln is
located in the BRCT1 domain responsible for interacting
with other repair components of BER. It was reported that
Arg→Gln substitution produces significant conforma-
tional changes at BRCT1 domain that may be critical for
DNA repair protein-protein interactions [37], thus
absence or impairment repair may cause genome instabil-
ity and cancer occurrence. It is also important to integrate
DNA-repair process with DNA-damage checkpoints and
cell survival, to evaluate the role of DNA repair at both cel-
lular and organismic levels. Therefore, protective effects of
XRCC1 polymorphisms in cancer may also be observed
by the enhanced efficiency of apoptosis at a cellular level
as a result of diminished DNA repair capacity secondary to
the genetic polymorphisms [38,39].
In our study, neither of these SNPs was found to individ-
ually contribute to head and neck cancer risk. There were
no differences between the distribution of the genotypes
or alleles frequences in patients and controls. However,
Table 1: The characteristic of patients group with squamous cell carcinoma of the head and neck (HNSCC).
Patients Sex Tumor stage
(TNM)
Smoking status
(cigarettes per day)
No. men women T N M non 10cc* 20cc* 20cc***
1 2 3 4 0 1 2301
9 2 8 3 9 1 51 73 12 96 21 51 059 20 2 6 9 3 3 2 4
T (1–4) – size or direct extent of the primary tumor; N (0–3) – degree of spread to regional lymph nodes; M (0/1) – presence of metastasis; non – 
not smoking; * – smoking for ten years; ** – smoking for twenty years; *** – smoking for thirty years.Journal of Experimental & Clinical Cancer Research 2009, 28:37 http://www.jeccr.com/content/28/1/37
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we found statistically non-significant increase of
Arg194Trp genotype frequency (OR, 1.37; 95% CI, 0.70–
2.68) and Trp194 allele (OR, 1.32; 95% CI, 0.70–2.49)
according to wild-type of Arg194Arg reference genotype
and Arg194  allele frequency (table 2). Non-statistical
increase of Arg399Gln (OR, 1.10; 95% CI, 0.61–1.97)
according to reference genotype of Arg399Arg was also
found. (table 3). While, no altered risk has been found
individually for the XRCC1 Arg194Trp or Arg399Gln pol-
ymorphisms, the halophyte analysis according to wild-
type of Arg194Arg-Arg399Arg showed high association
with head and neck cancer (table 4). The findings indi-
cated that a statistically non-significantly increased risk of
HNSCC was associated with the combined Arg194Arg-
Arg399Gln genotype (OR, 1.33; 95% CI, 0.70–2.56). The
higher risk of head and neck cancer occurrence was asso-
ciated with the combined Arg194Trp-Arg399Arg genotype
(OR, 2.96; 95% CI, 1.01–8.80) but no altered risk was
associated with others haplotypes. For Tyr165Tyr geno-
type we also observed positive correlation with cancer
progression assessed by tumor size (OR 4.56; 95% CI
1.60–12.95).
We also analyzed the distribution of genotypes and fre-
quency of alleles in groups of patients suffer head and
neck cancer according to different cancer staging by TNM
classification (table 5 and table 6). We did not find any
association of the Arg194Tyr or Arg399Gln polymor-
phisms in patients group with cancer progression assessed
by with tumour size (T) and node status (N). Addition-
ally, as a high risk factor for head and neck cancer occur-
rence we analysed patients with positive smoking status
within HNSCC group according to smokers selected from
controls (table 7 and table 8). While, no statistically sig-
nificant differences in distribution of the Arg194Tyr geno-
type was calculated, we found statistically significant
associations of Arg399Gln polymorphic variants of
XRCC1 gene with cancer risk within smoking group of
HNSCC patients. We found that Arg399Gln genotype fre-
quency (OR, 2.70; 95% CI, 1.26–5.78) and Gln399 allele
(OR, 4.31; 95% CI, 2.29–8.13) was associated with
patients group smoked ten or more cigarettes per day for
at least ten years. On the other hand Arg399Arg wild-type
genotype (OR, 0.18; 95% CI, 0.08–0.39) and Arg399
allele (OR, 0.22; 95% CI, 0.12–0.41) had protective effect
on cancer risk even in patients group with positive smok-
ing status.
The XRCC1 gene polymorphisms have been extensively
studied in the association with various human cancers
mostly breast, lung or head and neck carcinomas. Major
studies of head and neck cancer has been focused on pol-
ymorphisms of genes encoding enzymes of xenobiotic
metabolism and DNA repair [32,40]. Carriers of the
XRCC1 Arg399Gln variant have been shown to have
higher levels of DNA adducts [16] and to be at greater risk
for ionizing radiation sensitivity [17] and tobacco corre-
lated DNA damage [18-20]. Recently, Sreeja at al (2008)
has shown that the carriers of XRCC1 Gln399Gln geno-
types were at higher risk of lung cancer [12]. On the other
hand, López-Cima et al. (2007) has been reported that
individuals homozygous for the XRCC1 Gln339 allele
presented no risk of developing lung cancer [6]. The asso-
ciation between XRCC1 Arg399Gln polymorphism and
ductal carcinoma of women with breast cancer was found
statistically significant in studies performed by Dufloth et
al. at 2008 [13]. Despite of large number of studies, in
well-characterized populations, results from HNSCC
patients are still confusing. There was a marginally signif-
icant risk of HNSCC observed in variants of XRCC1 geno-
type with Trp194 allele in Thailand population [41]. No
altered risk was associated with the XRCC1 Arg399Gln
genotype in Li et al. studies [42], however smokers carry-
ing risk genotype of XRCC1 with dominant Gln399 allele
were over-represented in head and neck cancer popula-
tions from eastern region of India [43]. Recently, combi-
national polymorphisms of four DNA repair genes
XRCC1, XRCC2, XRCC3, and XRCC4 and their associa-
tion with HNSCC cancer in Taiwan has been investigated.
[14]. Except for XRCC2, none of SNPs was found to indi-
vidually contribute to cancer risk. In our study, we found
that Gln399 allele may also increase head and neck cancer
risk in population with positive smoking status. Finally,
no association was found individually for either analyzed
SNPs but we evidenced that combined genotypes of
XRCC1 may have impact on HNSCC risk.
Table 2: Distribution of genotypes and frequency of alleles of the Arg/Trp 194 (C/T 26304 exon 6) polymorphism of XRCC1 gene in 
squamous cell carcinoma of the head and neck (HNSCC) patients and the controls.
Genotype Allele HNSCC patients
(n = 92)
Number (frequency)
Controls
(n = 124)
Number (frequency)
OR (95% CI)
Arg/Arg 71 (0.86) 102 (0.82) 1 (reference)
Arg/Trp 21 (0.14) 22 (0.18) 1.37 (0.70; 2.68)
Trp/Trp 0 (0.00) 0 (0.00) ---------
Arg 163 (0.98) 226 (0.91) 1 (reference)
Trp 21 (0.12) 22 (0.09) 1.32 (0.70; 2.49)Journal of Experimental & Clinical Cancer Research 2009, 28:37 http://www.jeccr.com/content/28/1/37
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Table 3: Distribution of genotypes and frequency of alleles of the Arg/Gln 399 (G/A 28152 exon 9) polymorphism of XRCC1 gene in 
squamous cell carcinoma of the head and neck (HNSCC) patients and the controls.
Genotype Allele HNSCC patients
(n = 92)
Number (frequency)
Controls
(n = 124)
Number (frequency)
OR (95% CI)
Arg/Arg 37 (0,40) 49 (0.40) 1 (reference)
Arg/Gln 44 (0.48) 53 (0.43) 1.10 (0.61; 1.97)
Gln/Gln 11 (0.12) 22 (0.18) 0.66 (0.29; 1.53)
Arg 118 (0.64) 151 (0.61) 1 (reference)
Gln 66 (0.36) 97 (0.39) 0.87 (0.59; 1.29)
Table 4: Haplotypes distribution and frequencies of XRCC1 gene polymorphisms in squamous cell carcinoma of the head and neck 
(HNSCC) patients and the controls.
Haplotypes XRCC1-194–399 HNSCC patients
(n = 92)
Number (frequency)
Controls
(n = 124)
Number (frequency)
OR (95% CI)
Arg/Arg-Arg/Arg 29 (0,32) 43 (0,35) 1 (reference)
Arg/Trp-Arg/Arg 12 (0.13) 6 (0.05) 2.96 (1.01; 8.80)
Trp/Trp-Arg/Arg 0 (0.00) 0 (0.00) ---------
Arg/Arg-Arg/Gln 36 (0.39) 40 (0.32) 1.33 (0.70; 2.56)
Arg/Trp-Arg/Gln 8 (0,09) 13 (0,10) 0.91 (0.34; 2.48)
Trp/Trp-Arg/Gln 0 (0.00) 0 (0.00) ---------
Arg/Arg-Gln/Gln 6 (0.07) 19 (0.15) 0.47 (0.17; 1.31)
Arg/Trp-Gln/Gln 1 (0.01) 3 (0.02) 0.49 (0.05; 4.99)
Trp/Trp-Gln/Gln 0 (0,00) 0 (0,00) ---------
Table 5: The genotype and allele frequency and odds ratios (OR) of the Arg194Trp polymorphism of XRCC1 gene in patients with head 
and neck cancer with different tumor size and lymph node status.
Tumour size (T) Node status (N)
Genotype Allele T3 + T4
Number/Frequency
T1+ T2
Number/Frequency
OR (95% CI) N1 + N2 + N3
Number/Frequency
N0
Number/Frequency
OR (95% CI)
Arg/Arg 43 (0.72) 28 (0.88) 0.36 (0.11 – 1.19) 20 (0.67) 51 (0.82) 0.43 (0.16 – 1.67)
Arg/Trp 17 (0.28) 4 (0.12) 2.76 (0.84 – 9.08) 10 (0.33) 11 (0.18) 2.32 (0.85 – 6.30)
Trp/Trp 0 (0.00) 0 (0.00) --------- 0 (0.00) 0 (0.00) ---------
Arg 103 (0.86) 60 (0.96) 0.40 (0.13 – 1.27) 50 (0.83) 113 (0.91) 0.48 (0.19 – 1.32)
Trp 17 (0.14) 4 (0.14) 2.47 (0.80 – 7.70) 10 (0.17) 11 (0.09) 2.05 (0.82 – 5.14)
Table 6: The genotype and allele frequency and odds ratios (OR) of the Arg399Gln polymorphism of XRCC1 gene in patients with head 
and neck cancer with different tumor size and lymph node status.
Tumour size (T) Node status (N)
Genotype Allele T3 + T4
Number/Frequency
T1+ T2
Number/Frequency
OR (95% CI) N1 + N2 + N3
Number/Frequency
N0
Number/Frequency
OR (95% CI)
Arg/Arg 24 (0.40) 13 (0.41) 0,97 (0.41 – 2.34) 8 (0,27) 29 (0.47) 0.41 (0.16 – 1.07)
Arg/Gln 30 (0.50) 14 (0.44) 1.28 (0.54 – 3.05) 17 (0.57) 27 (0.44) 1.70 (0.70 – 4.08)
Gln/Gln 6 (0.10) 5 (0.16) 0.60 (0.17 – 2.14) 5 (0.17) 6 (0.10) 1.86 (0.52 – 6.70)
Arg 78 (0.65) 40 (0.62) 1.11 (0.59 – 2.09) 33 (0.55) 85 (0.69) 0.56 (0.30 – 1.06)
Gln 42 (0.35) 24 (0.38) 0.89 (0.48 – 1.68) 27 (0.45) 39 (0.31) 1.78 (0.94 – 3.36)Journal of Experimental & Clinical Cancer Research 2009, 28:37 http://www.jeccr.com/content/28/1/37
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Conclusion
Head and neck cancer patients have variable prognoses
even within the same clinical stage and while receiving
similar treatments. The number of studies of genetic pol-
ymorphisms as prognostic factors of HNSCC outcomes is
growing. Candidate polymorphisms have been evaluated
in DNA repair, cell cycle, xenobiotic metabolism, and
growth factor pathways. In our study, we assessed two
common polymorphisms of the XRCC1 gene that might
influence DNA repair capacity and their association with
head and neck cancer risk. Finally, we identified the com-
bined genotype of Arg194Trp-Arg399Arg that was associ-
ated with HNSCC cancer risk and may have an impact on
identification of a high-risk population.
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